<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343497</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00198-39</org_study_id>
    <nct_id>NCT02343497</nct_id>
  </id_info>
  <brief_title>Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia</brief_title>
  <acronym>LLAX</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel-group Design, Monocentric Study on Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajinomoto Foods Europe SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Polytechnique LaSalle Beauvais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naturalpha</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajinomoto Foods Europe SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether astaxanthin supplementation can impact&#xD;
      triglyceride plasmatic concentrations in volunteers presenting mild dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting plasma triglycerides</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting cholesterol</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>total cholesterol (g/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting HDL-cholesterol</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting LDL-cholesterol</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein A1</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein B</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein balance</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Apolipoprotein B over Apolipoprotein A1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting blood pressure</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
    <description>triplicate measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting heart rate</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>mU/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>homeostatic model assessment to quantify insulin resistance (HOMA-IR)</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>glucose (mg/dl) * insulin(U/l) / 405</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting adiponectin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting leptin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting ghrelin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting resistin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphatidylcholine hydroperoxides</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>HPLC/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmatic concentrations in astaxanthin</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
    <description>HPLC/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance with study product</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
    <description>accountability of returned used/unused caps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the 12 weeks of intervention</time_frame>
    <description>number of subjects with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Astaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>filling agent, in lipid capsules, 2 caps per day, duration 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Astaxanthin</intervention_name>
    <arm_group_label>Astaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be fulfilled at V0:&#xD;
&#xD;
          1. Male and female volunteers, able to read and write, aged from 18 to 60 years inclusive&#xD;
             at time of screening.&#xD;
&#xD;
          2. Smokers and no smokers.&#xD;
&#xD;
          3. Subject with a good physical condition confirmed based on the subject's interview and&#xD;
             the clinical exam performed by the investigator.&#xD;
&#xD;
          4. Subject with a Body Mass Index (BMI) ≥ 18,5 and &lt; 35 kg/m².&#xD;
&#xD;
          5. Written informed consent provided prior to screening, after receiving and&#xD;
             understanding the subject information.&#xD;
&#xD;
          6. Stable body weight (&lt; 3% variation) within the last 3 months prior to screening.&#xD;
&#xD;
          7. Subject registered with the French Social Security, in agreement with the French law&#xD;
             on biomedical experimentation.&#xD;
&#xD;
             To be fulfilled before V1, randomization visit:&#xD;
&#xD;
          8. Subject with fasting triglyceride concentration ≥ 1.2 and &lt; 4 g/l.&#xD;
&#xD;
          9. Subject with fasting serum LDL-cholesterol ≤ 2.2 g/l.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To be fulfilled at V0:&#xD;
&#xD;
          1. Subject taking lipid altering drug therapy within 6 weeks prior to screening. Also&#xD;
             excluded are supplements known to have significant lipid altering effects, such as:&#xD;
&#xD;
               -  Phytosterols or phytostanols,&#xD;
&#xD;
               -  Red yeast rice extract (Monascus purpureus),&#xD;
&#xD;
               -  Beta-glucans,&#xD;
&#xD;
               -  Omega-3 fatty acids (alpha-linolenic, docosahexaenoic and eicosapentaenoic),&#xD;
&#xD;
          2. Subject using the following medications: systemic corticosteroids (nasal and inhaled&#xD;
             corticosteroids are permitted), orlistat, bile acid resins, prescription omega-3 fatty&#xD;
             acids, cyclical or non continuous hormone therapy (estrogen or testosterone) excepted&#xD;
             stable oestroprogestative or progestative contraception i.e. started at least three&#xD;
             months preceding the screening visit.&#xD;
&#xD;
          3. Intake of oestroprogestative or progestative contraception started within less than&#xD;
             three months preceding the screening visit.&#xD;
&#xD;
          4. Subject taking antioxidant agents or vitamins within 6 weeks prior to screening.&#xD;
&#xD;
          5. Subject taking astaxanthin-rich foods (red fish and seafood, mostly) or supplements&#xD;
             (including krill).&#xD;
&#xD;
          6. Subject following any special diet including, but not limited to liquid, high or low&#xD;
             protein, raw food, vegetarian or vegan, etc.&#xD;
&#xD;
          7. Subject with any sensitivity or allergy to any of the products used in this clinical&#xD;
             trial.&#xD;
&#xD;
          8. Subject that consume more than three (3) units of alcoholic beverage daily. For the&#xD;
             purpose of this study, a unit of alcohol is defined as 400 ml of beer, 200 ml of wine&#xD;
             or 50 ml of hard spirits.&#xD;
&#xD;
          9. Subject with known human immunodeficiency virus (HIV) seropositivity.&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding, or planning a pregnancy during the duration&#xD;
             of the study.&#xD;
&#xD;
         11. Female subject without efficient contraceptive method: hormonal contraception&#xD;
             (including patch, contraceptive ring, etc.), intra-uterine device or other mechanical&#xD;
             contraception method (condom or diaphragm) or spermicide for all the duration of the&#xD;
             study.&#xD;
&#xD;
         12. Subject treated for type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
         13. Subject with known cardiovascular disease or stroke, except for conditions that are&#xD;
             deemed clinically insignificant by the investigator.&#xD;
&#xD;
         14. Subject with symptomatic hypertension, treated or not.&#xD;
&#xD;
         15. Subject treated by antivitamin K.&#xD;
&#xD;
         16. Subject with history of significant gastrointestinal disease such as severe&#xD;
             constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g.&#xD;
             Crohn's disease, ulcerative colitis) and all kind of gastrointestinal surgery.&#xD;
&#xD;
         17. Subject with thyroid dysfunction or treatment for this pathology.&#xD;
&#xD;
         18. Subject with history of severe psychiatric illness which in the opinion of the&#xD;
             investigator would interfere with the optimal participation in the study.&#xD;
&#xD;
         19. Subject with history of cancer within 5 years of screening visit (except for&#xD;
             successfully treated basal and squamous cell carcinoma of the skin).&#xD;
&#xD;
         20. Subject with any medical contraindication to blood sampling (anemia, clotting defect).&#xD;
&#xD;
         21. Subject practicing intense physical activity (sport, physical exertion at work).&#xD;
&#xD;
         22. Subject with history of drug abuse.&#xD;
&#xD;
         23. Participation to any other clinical trial simultaneously and/or within 1 month prior&#xD;
             to screening.&#xD;
&#xD;
         24. Subject who in the opinion of the investigator have a risk of non-compliance to the&#xD;
             study procedures or who are otherwise not appropriate to include in this clinical&#xD;
             trial.&#xD;
&#xD;
         25. Subject of legal age unable of giving consent.&#xD;
&#xD;
         26. Subject deprived of liberty by judicial or administrative decision.&#xD;
&#xD;
         27. Subject of legal age under legal protection.&#xD;
&#xD;
         28. Subject having received over 4500 euros for clinical trial participation within the&#xD;
             prior year including the indemnity for the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Nutrition Clinique Naturalpha</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

